Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Roche says the move marks a step forward in its digital transformation strategy
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
The 7,000th store was inaugurated in Ayodhya, Uttar Pradesh
Subscribe To Our Newsletter & Stay Updated